[
  {
    "ts": null,
    "headline": "Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%",
    "summary": "Pfizer Inc. (NYSE:PFE) on Friday released data from Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The study showed statistically significant and clinically meaningful survival results. The data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New E",
    "url": "https://finnhub.io/api/news?id=2627d43edaa8ddf0033a85036833d3c7cd78222095cdc401cfc632ffb2256fd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748632236,
      "headline": "Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%",
      "id": 134908580,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) on Friday released data from Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The study showed statistically significant and clinically meaningful survival results. The data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New E",
      "url": "https://finnhub.io/api/news?id=2627d43edaa8ddf0033a85036833d3c7cd78222095cdc401cfc632ffb2256fd9"
    }
  },
  {
    "ts": null,
    "headline": "ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC",
    "summary": "Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.",
    "url": "https://finnhub.io/api/news?id=85b3889d58b369d173eba5a8babe83cdcfc7b434ce5aa66488562480be09a265",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748619777,
      "headline": "ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC",
      "id": 134906496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.",
      "url": "https://finnhub.io/api/news?id=85b3889d58b369d173eba5a8babe83cdcfc7b434ce5aa66488562480be09a265"
    }
  },
  {
    "ts": null,
    "headline": "US CDC keeps COVID vaccine option for healthy children",
    "summary": "The U.S. Centers for Disease Controland Prevention said COVID-19 vaccines remain an option forhealthy children when parents and doctors agree that it isneeded, stopping short of Health Secretary...",
    "url": "https://finnhub.io/api/news?id=8a476060550b157af5c6d4684ac41c48ac747cfa2a1e7bea397ccf9a23ac7b54",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748618347,
      "headline": "US CDC keeps COVID vaccine option for healthy children",
      "id": 134910388,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. Centers for Disease Controland Prevention said COVID-19 vaccines remain an option forhealthy children when parents and doctors agree that it isneeded, stopping short of Health Secretary...",
      "url": "https://finnhub.io/api/news?id=8a476060550b157af5c6d4684ac41c48ac747cfa2a1e7bea397ccf9a23ac7b54"
    }
  },
  {
    "ts": null,
    "headline": "US CDC continues to recommend COVID vaccines for children, contradicts Kennedy",
    "summary": "The U.S. Centers for Disease Control and Prevention is stillrecommending COVID-19 vaccines for healthy children, according to its latest publishedimmunization schedule, contradicting Health and...",
    "url": "https://finnhub.io/api/news?id=6d496b919a042a7ed0faaf174648a557986341f2e2b70794c82c8bb6285e5ff7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748618347,
      "headline": "US CDC continues to recommend COVID vaccines for children, contradicts Kennedy",
      "id": 134907743,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. Centers for Disease Control and Prevention is stillrecommending COVID-19 vaccines for healthy children, according to its latest publishedimmunization schedule, contradicting Health and...",
      "url": "https://finnhub.io/api/news?id=6d496b919a042a7ed0faaf174648a557986341f2e2b70794c82c8bb6285e5ff7"
    }
  },
  {
    "ts": null,
    "headline": "US CDC continues to recommend COVID vaccines for healthy children",
    "summary": "The U.S. Centers for Disease Control and Prevention is stillrecommending COVID-19 vaccines for healthy children, according to its latest publishedimmunization schedule. The schedule,...",
    "url": "https://finnhub.io/api/news?id=0701a90ca0def876c04ee4eac585f51e679143742527827495c4bbc5169b128b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748618347,
      "headline": "US CDC continues to recommend COVID vaccines for healthy children",
      "id": 134907496,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. Centers for Disease Control and Prevention is stillrecommending COVID-19 vaccines for healthy children, according to its latest publishedimmunization schedule. The schedule,...",
      "url": "https://finnhub.io/api/news?id=0701a90ca0def876c04ee4eac585f51e679143742527827495c4bbc5169b128b"
    }
  },
  {
    "ts": null,
    "headline": "US CDC keeps recommendation of COVID vaccines for healthy kids",
    "summary": "The U.S. Centers for Disease Control and Prevention isstill recommending COVID-19 vaccines for healthy children, according to its latest publishedimmunization schedule. The schedule,...",
    "url": "https://finnhub.io/api/news?id=909b5ae7eb7d0b948dc52be7c7849343a28bdd8a0b8b0e8c10699966955defeb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748618347,
      "headline": "US CDC keeps recommendation of COVID vaccines for healthy kids",
      "id": 134907296,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. Centers for Disease Control and Prevention isstill recommending COVID-19 vaccines for healthy children, according to its latest publishedimmunization schedule. The schedule,...",
      "url": "https://finnhub.io/api/news?id=909b5ae7eb7d0b948dc52be7c7849343a28bdd8a0b8b0e8c10699966955defeb"
    }
  },
  {
    "ts": null,
    "headline": "US CDC keeps recommendation of COVID vaccines for healthy kids, report says",
    "summary": "The U.S. Centers forDisease Control and Prevention is still recommending COVIDvaccines for healthy children, the Washington Post reported onFriday, citing the CDC's latest published immunization...",
    "url": "https://finnhub.io/api/news?id=3296ef9eae6673055ae88689582e31226765063e2d866276351a53ad980d216b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748616187,
      "headline": "US CDC keeps recommendation of COVID vaccines for healthy kids, report says",
      "id": 134906861,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "The U.S. Centers forDisease Control and Prevention is still recommending COVIDvaccines for healthy children, the Washington Post reported onFriday, citing the CDC's latest published immunization...",
      "url": "https://finnhub.io/api/news?id=3296ef9eae6673055ae88689582e31226765063e2d866276351a53ad980d216b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
    "summary": "NEW YORK, May 30, 2025--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These data will be presented today in an oral presentation (Abstract LBA3500) at the 2025 American Society",
    "url": "https://finnhub.io/api/news?id=0a6e08744d9cf3fda8dee35bdd2cbd52321b5719a822183074ae18d018a4a5ef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748606400,
      "headline": "Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
      "id": 134899284,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, May 30, 2025--Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These data will be presented today in an oral presentation (Abstract LBA3500) at the 2025 American Society",
      "url": "https://finnhub.io/api/news?id=0a6e08744d9cf3fda8dee35bdd2cbd52321b5719a822183074ae18d018a4a5ef"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: colorectal cancer mortality halved",
    "summary": "Pfizer announced Friday that a treatment based on its oral small molecule Braftovi has halved the risk of death in aggressive metastatic colorectal cancer in a Phase 3 clinical trial.The combination...",
    "url": "https://finnhub.io/api/news?id=1ebb12016679652f7e71a82b99d5633d87b5f88f78b8c246cf7a09e7397bfead",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748601689,
      "headline": "Pfizer: colorectal cancer mortality halved",
      "id": 134902207,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer announced Friday that a treatment based on its oral small molecule Braftovi has halved the risk of death in aggressive metastatic colorectal cancer in a Phase 3 clinical trial.The combination...",
      "url": "https://finnhub.io/api/news?id=1ebb12016679652f7e71a82b99d5633d87b5f88f78b8c246cf7a09e7397bfead"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6",
    "summary": "Pfizer Inc. announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI®? in combination with cetuximab and mFOLFOX6 in...",
    "url": "https://finnhub.io/api/news?id=029497fc2a583de12a9f0b6655d32b08ac1e31149655b920516abdc0a065163e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748598653,
      "headline": "Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6",
      "id": 134898313,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Inc. announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI®? in combination with cetuximab and mFOLFOX6 in...",
      "url": "https://finnhub.io/api/news?id=029497fc2a583de12a9f0b6655d32b08ac1e31149655b920516abdc0a065163e"
    }
  },
  {
    "ts": null,
    "headline": "Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.",
    "summary": "Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.",
    "url": "https://finnhub.io/api/news?id=2b7e5753858cac98c4224c9792e2ddd967d1f77dbd0e072cd9a34c02b4ea529f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748597220,
      "headline": "Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.",
      "id": 134898216,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.",
      "url": "https://finnhub.io/api/news?id=2b7e5753858cac98c4224c9792e2ddd967d1f77dbd0e072cd9a34c02b4ea529f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Oral Obesity Drug Flop - A Symptom Of A Deeper Pipeline Problem",
    "summary": "Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find out why PFE stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=ec708562d50f388639deef0bff80c70f7a74cafff04ec0969b538dbd8a6da872",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748595127,
      "headline": "Pfizer's Oral Obesity Drug Flop - A Symptom Of A Deeper Pipeline Problem",
      "id": 134894789,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1542412784/image_1542412784.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find out why PFE stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=ec708562d50f388639deef0bff80c70f7a74cafff04ec0969b538dbd8a6da872"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Says Braftovi Combination Regimen Met Trial's Dual Primary Endpoint",
    "summary": "Pfizer Inc: * PFIZER: BRAFTOVI COMBINATION REGIMEN CUTS RISK OF DEATH INHALFFOR PATIENTS WITH BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER * PFIZER: BREAKWATER SURVIVAL...",
    "url": "https://finnhub.io/api/news?id=9ea9e24744fe351744de7146c6400c4699998929bb91b2e4cf5a6850860e80ad",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748593028,
      "headline": "Pfizer Says Braftovi Combination Regimen Met Trial's Dual Primary Endpoint",
      "id": 134894174,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Inc: * PFIZER: BRAFTOVI COMBINATION REGIMEN CUTS RISK OF DEATH INHALFFOR PATIENTS WITH BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER * PFIZER: BREAKWATER SURVIVAL...",
      "url": "https://finnhub.io/api/news?id=9ea9e24744fe351744de7146c6400c4699998929bb91b2e4cf5a6850860e80ad"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes",
    "summary": "Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration with Acepodia and faces mounting lawsuits over its contraceptive, Depo-Provera. The decision to mutually terminate the partnership with Acepodia, which focused on autoimmune disease drug development, is attributed to PFE’s global resource prioritization and not to […]",
    "url": "https://finnhub.io/api/news?id=add99063cf9a8fba6e31809a67253631ce01efbeb057f484d38252c224de51e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748575784,
      "headline": "Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes",
      "id": 134880066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is navigating a period of strategic upheaval and legal scrutiny as it ends its clinical collaboration with Acepodia and faces mounting lawsuits over its contraceptive, Depo-Provera. The decision to mutually terminate the partnership with Acepodia, which focused on autoimmune disease drug development, is attributed to PFE’s global resource prioritization and not to […]",
      "url": "https://finnhub.io/api/news?id=add99063cf9a8fba6e31809a67253631ce01efbeb057f484d38252c224de51e2"
    }
  }
]